29. Taneja SS. Optimizing prostate biopsy strategies for the diagnosis of prostate cancer. Rev Urol. 2003;5(3):149-155.
30. Delongchamps NB, Singh A, Hass GP. The role of prevalence in the diagnosis of prostate cancer. Cancer Control. 2006;13(3):158-168.
31. Baumgart LA, Gerling GJ, Bass EJ. Characterizing the range of simulated prostate abnormalities palpable by digital rectal examination. Cancer Epidemiol. 2010;34(1):79-84.
32. Crawford ED, Schutz MJ, Clejan S, et al. The effect of digital rectal examination on prostate-specific antigen levels. JAMA. 1992;267(16):2227-2228.
33. Stephens NJ, Bharwani N, Heenan SD. Prostate cancer staging. Imaging. 2008;20:112-121.
34. Richman JM, Carter HB, Hanna MN, et al. Efficacy of periprostatic local anesthetic for prostate biopsy analgesia: a meta-analysis. Urology. 2006;67(6):1224-1228.
35. Luscombe CJ, Cooke PW. Pain during prostate biopsy. Lancet. 2004;363(9424):1840-1841.
36. Yun TJ, Lee HJ, Kim SH, et al. Does the intrarectal instillation of lidocaine gel before periprostatic neurovascular bundle block during transrectal ultrasound-guided prostate biopsies improve analgesic efficacy? A prospective, randomized trial. J Urol. 2007;178(1):103-106.
37. Lee HY, Lee HJ, Byun SS, et al. Effect of intraprostatic local anesthesia during transrectal ultrasound guided prostate biopsy: comparison of 3 methods in a randomized, double-blind, placebo controlled trial. J Urol. 2007;178(2):469-472.
38. Giannarini G, Mogorovich, A, Valent F, et al. Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy: results of a prospective randomized trial. Urology. 2007;70(3): 501-505.
39. Park DS, Oh JJ, Lee JH, et al. Simple use of the suppository type povidone-iodine can prevent infectious complications in transrectal ultrasound-guided prostate biopsy. Adv Urol. 2009:750598. Epub 2009 Apr 23.
40. Rietbergen JB, Kruger AE, Kranse R, Schröder FH. Complications of transrectal ultrasound–guided systemic sextant biopsies of the prostate: evaluation of complication rates and risks factors within a population-based screening program. Urology. 1997;49(6):875-880.
41. Weber B, Saliken J, Jadavji T, et al. A near-fatal case of sepsis with an antibiotic-resistant organism complicating a routine transrectal prostate biopsy in a health care worker. Can Urol Assoc J. 2008;2 (5):543-545.
42. Vaghefi H, Magi-Galluzzi C, Klein EA. Local recurrence of prostate cancer in rectal submucosa after transrectal needle biopsy and radical prostatectomy. Urology. 2005;66(4):881.
43. Widmark A, Klepp O, Solberg A, et al; Swedish Association for Urological Oncology 3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009; 373(9660):301-308.
44. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280(11):975-980.
45. Johansson JE, Andrén O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291(22):2713-2719.
46. Bill-Axelson A, Holmberg L, Filén F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial. J Natl Cancer Inst. 2008;100(16):1144-1154.
47. Inman BA, Davies JD, Rangel LJ, et al. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. Cancer. 2008;113(7):1544-1551.
48. Klotz L. Active surveillance for prostate cancer: patient selection and management. Curr Oncol. 2010;17 suppl 2:S111-S117.
49. Oxford Radcliffe Hospital, National Cancer Institute. Active surveillance, radical prostatectomy, or radiation therapy in treating patients with localized prostate cancer; NCT00632983. http://clinicaltrials.gov/ct2/show/NCT00632983?term=prostate%2C+surveillance&rank=7. Accessed December 21, 2010.
50. NCIC Clinical Trials Group, National Cancer Institute, Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, Southwest Oncology Group. Observation or radical treatment in patients with prostate cancer; NCT00499174. http://clinicaltrials.gov/ct2/show/NCT00499174? term=prostate%2C+surveillance&rank=12. Accessed December 21, 2010.
51. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302(11): 1202-1209.
52. Catalona WJ, Carvalhal GF, Mager DE, Smith DS. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol. 1999;162(2):433-438.
53. D’Amico AV, Manola J, Loffredo M, et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292(7):821-827.
54. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008; 299(23):2760-2769.
55. de Bono JS, Oudard S, Ozguroglu M, et al; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-1154.
56. US Food and Drug Administration (FDA news release, June 17, 2010). FDA approves new treatment for advanced prostate cancer. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm216143.htm Accessed December 21, 2010.
57. Cancer and Leukemia Group B, National Cancer Institute, Eastern Cooperative Oncology Group. Docetaxel and prednisone with or without bevacizumab in treating patients with prostate cancer that did not respond to hormone therapy; NCT00110214. http://clinicaltrials.gov/ct2/show/NCT00110214. Accessed December 21, 2010.